Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering Daclatasvir

Client Email

Product

Daclatasvir
Asunaprevir
US Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

Bora Pharmaceuticals- Making success more certain.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

Contact Supplier

Axplora- The partner of choice for complex APIs.

Contact Supplier

Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

Contact Supplier

Daclatasvir

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

28 API Suppliers, 5 USDMF, 6 EU WC, 5 NDC API, 22 Listed Suppliers, $ API Reference Price

28 API Suppliers
5 USDMF
6 EU WC
5 NDC API
22 Listed Suppliers
$ API Reference Price

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Imports

INTERMEDIATES

9 API Suppliers

9 API Suppliers

FINISHED DOSAGE FORMULATIONS

12 FDF Dossiers, 3 FDA Orange Book, 6 Europe, 3 Listed Dossiers

12 FDF Dossiers
3 FDA Orange Book
6 Europe
3 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 30MG BASE, TABLET;ORAL - EQ 60MG BASE, TABLET;ORAL - EQ 90MG BASE

TABLET;ORAL - EQ 30MG BASE
TABLET;ORAL - EQ 60MG BASE
TABLET;ORAL - EQ 90MG BASE

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 3 DKSH, 1 Jai Radhe Sales, 7 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Clariant, 10 Corel Pharma Chem, 4 DFE Pharma, 6 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 21 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 9 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 10 Roquette, 6 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 9 Sigachi Industries, 2 The Dow Chemical Company, 3 Vasa Pharmachem

1 SPI Pharma
3 DKSH
1 Jai Radhe Sales
7 Gangwal Healthcare
1 Nanjing Well Pharmaceutical
1 ACG Worldwide
6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 Clariant
10 Corel Pharma Chem
4 DFE Pharma
6 Gangwal Chemicals
5 Ideal Cures Pvt Ltd
1 Ingredion Pharma Solutions
21 Kerry
3 Kima Chemical
6 Lonza Capsugel
9 Microlex e.U
1 Novo Excipients
1 Pharmatrans-Sanaq
2 Pluviaendo
3 Prachin Chemical
1 Qianhao Chemical (Hebei) Co., Ltd
1 Qualicaps
10 Roquette
6 Seppic
4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
9 Sigachi Industries
2 The Dow Chemical Company
3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 31 Fillers, Diluents & Binders, 20 Controlled & Modified Release, 17 Direct Compression, 15 Disintegrants & Superdisintegrants, 13 Thickeners and Stabilizers, 11 Lubricants & Glidants, 10 Granulation, 9 Co-Processed Excipients, 8 Film Formers & Plasticizers, 5 Empty Capsules, 4 Emulsifying Agents, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Taste Masking, 4 Coloring Agents, 3 Chewable & Orodispersible Aids, 2 Topical, 1 Parenteral, 1 Surfactant & Foaming Agents, 1 Solubilizers

44 Coating Systems & Additives
31 Fillers, Diluents & Binders
20 Controlled & Modified Release
17 Direct Compression
15 Disintegrants & Superdisintegrants
13 Thickeners and Stabilizers
11 Lubricants & Glidants
10 Granulation
9 Co-Processed Excipients
8 Film Formers & Plasticizers
5 Empty Capsules
4 Emulsifying Agents
4 Rheology Modifiers
4 Vegetarian Capsules
4 API Stability Enhancers
4 Taste Masking
4 Coloring Agents
3 Chewable & Orodispersible Aids
2 Topical
1 Parenteral
1 Surfactant & Foaming Agents
1 Solubilizers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 44 NEWS #PharmaBuzz

3 DATA COMPILATION #PharmaFlow
44 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

4 Finished Drug Prices, 5 Annual Reports

4 Finished Drug Prices
5 Annual Reports

MARKET PLACE

6 APIs

6 APIs

PATENTS & EXCLUSIVITIES

18 US Patents, 4 Health Canada Patents

18 US Patents
4 Health Canada Patents

$ API Ref.Price (USD/KG) : 654 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

18 All

01 18BRISTOL-MYERS SQUIBB

filter Patent Number Reset all filters

18 All

01 28329159

02 28629171

03 48642025

04 48900566

05 69421192

filter API Patent Reset all filters

18 All

01 14Y

02 4Blank

filter FDF Patent Reset all filters

18 All

01 6Y

02 12Blank

filter Expiration Date Reset all filters

18 All

01 102027-08-08

02 42027-08-11

03 22029-07-24

04 22031-06-13

US Patents
Health Canada Patents

Product Main Page

01

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8900566

Drug Substance Claim :

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8900566

Drug Substance Claim :

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8900566

Drug Substance Claim :

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-11

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8642025

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-11

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 9421192

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 9421192

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-08

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 9421192

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 206843

Patent Use Code : U-1725

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-08

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-08-11

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8642025

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2027-08-11

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-13

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8629171

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2031-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

BRISTOL-MYERS SQUIBB

DACLATASVIR DIHYDROCHLORIDE

Luxepack

Not Confirmed

BRISTOL-MYERS SQUIBB

Luxepack

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2031-06-13

DACLATASVIR DIHYDROCHLORIDE

US Patent Number : 8629171

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 206843

Patent Use Code : U-1724

Delist Requested :

Patent Use Description : METHOD OF INHIBITING H...

Patent Expiration Date : 2031-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?